Mave Health has introduced a $495 neuromodulation headset designed to support attention, mood regulation and stress management. The device is positioned as a consumer product and does not require medical regulatory approval.
Innovation Driven By Personal Tragedy
The company was founded in 2023 by Dhawal Jain, together with Jai Sharma and Aman Kumar. Jain said the idea was shaped by personal experience during the COVID-19 period, which highlighted challenges in measuring progress in mental health treatment. Focus shifted to neuromodulation as a way to introduce measurable outcomes in areas such as stress and productivity.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
Leveraging TDCS For Lifestyle Enhancement
The company was founded in 2023 by Dhawal Jain, together with Jai Sharma and Aman Kumar. Jain said the idea was shaped by personal experience during the COVID-19 period, which highlighted challenges in measuring progress in mental health treatment. Focus shifted to neuromodulation as a way to introduce measurable outcomes in areas such as stress and productivity.
Rigorous Beta Testing And Preliminary Results
During private beta trials conducted between 2024 and 2025, more than 500 users reported significant improvements. Nearly 80% of participants experienced a 60% boost in productivity, while 75% noted a reduction in stress levels within two months of use. Complemented by a robust app that tracks metrics such as mood, focus, stress, and heart rate variability, the system offers insights into long-term trends, allowing both users and the company to measure its impact accurately.
Expert Perspectives And Ongoing Studies
External experts have highlighted both potential and limitations. Himanshu Nirvan, a psychiatrist who consulted on the project, pointed to the device’s accessibility and portability. Leigh Elkins Charvet of NYU Grossman School of Medicine noted that while tDCS is considered safe in controlled settings, broader consumer use requires further evidence and clearer guidelines. The company has conducted four observational studies involving 200 participants, with results currently under academic review.
Strategic Market Positioning And Investment Milestones
By marketing the headset as a non-medical lifestyle device, Mave Health aims to bypass the protracted regulatory pathways and reach a wider audience. The company’s innovative approach is supported by recent seed funding of $2.1 million led by Blume Ventures, with notable participation from investors such as Tesla Autopilot AI lead Dhaval Shroff. With under $3 million raised in total, Mave Health is set to begin shipping its first batch to customers in the U.S. and India in April 2026.
This evolution not only marks a turning point in consumer mental health technology but also underscores the broader trend of integrating advanced neuromodulation techniques into everyday wellness routines. As research continues and more clinical evidence emerges, the future of mental health management could very well be defined by such portable, scalable innovations.
